Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
20 août 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
07 août 2024 16h11 HE | Catalyst Pharmaceuticals, Inc.
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch Reported Record Q2 2024 Total Revenues of $122.7 Million,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
28 mai 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
08 mai 2024 16h16 HE | Catalyst Pharmaceuticals, Inc.
Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
28 mars 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
27 mars 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing,...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)
13 mars 2024 07h55 HE | Catalyst Pharmaceuticals, Inc.
AGAMREE® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE
27 févr. 2024 08h03 HE | Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
04 déc. 2023 08h03 HE | Catalyst Pharmaceuticals, Inc.
Ms. Alicia Grande, Catalyst's Current CFO, to Retire at the End of 2023 Dr. Steven Miller Promoted to Executive Vice President, Chief Operating and Scientific Officer and Jeffrey Del Carmen Promoted...
RactigenLogo.png
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting
02 nov. 2023 08h00 HE | Ractigen Therapeutics
Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting